Abstract
BackgroundAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein/ligand 1 (PD-1/PD-L1) are approved for treatment of multiple cancer types. Chemotherapy is often...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have